Key result
Inhibition of TRPC6 and CaMKII with SAR7334 and KN-93 significantly alleviated high glucose-induced cardiomyocyte apoptosis and proliferation inhibition.
Why the study?
Diabetic cardiomyopathy is a serious complication of end-stage diabetes, and the study aimed to explore whether TRPC6 affects cardiomyocyte apoptosis and proliferation inhibition in DCM.
Does inhibition of TRPC6 or CaMKII alleviate cardiomyocyte apoptosis and proliferation inhibition in a high-glucose environment?
Does inhibition of TRPC6 or CaMKII alleviate cardiomyocyte apoptosis and proliferation inhibition in a high-glucose environment?
p-value: p=<0.0001
Inhibition of the TRPC6/P-CaMKII pathway may alleviate cardiomyocyte apoptosis and proliferation inhibition in diabetic cardiomyopathy models.
May alleviate high-glucose cardiomyocyte injury in vitro; hypothesis-generating for TRPC6/CaMKII targeting in diabetic cardiomyopathy.
BACKGROUND: Diabetic cardiomyopathy (DCM) is a serious complication of end-stage diabetes that presents symptoms such as cardiac hypertrophy and heart failure. The transient receptor potential channel 6 (TRPC6) protein is a very important selective calcium channel that is closely related to the development of various cardiomyopathies. AIM: To explore whether TRPC6 affects cardiomyocyte apoptosis and proliferation inhibition in DCM. METHODS: We compared cardiac function and myocardial pathological changes in wild-type mice and mice injected with streptozotocin (STZ), in addition to comparing the expression of TRPC6 and P-calmodulin-dependent protein kinase II (P-CaMKII) in them. At the same time, we treated H9C2 cardiomyocytes with high glucose and then evaluated the effects of addition of SAR, a TRPC6 inhibitor, and KN-93, a CaMKII inhibitor, to such H9C2 cells in a high-glucose environment. RESULTS: , the expression of TRPC6 and P-CaMKII increased in a high-glucose environment. However, addition of inhibitors to H9C2 cells in a high-glucose environment resulted in alleviation of both apoptosis and proliferation inhibition. CONCLUSION: The inhibition of apoptosis and proliferation of cardiomyocytes in a high-glucose environment may be closely related to activation of the TRPC6/P-CaMKII pathway.
No takes yet. Share an insight, caveat, or question.
Shijun Jiang (2022) studied Diabetic cardiomyopathy (n=20). TRPC6 inhibitor (SAR7334) and CaMKII inhibitor (KN-93) vs. High glucose environment without inhibitors was evaluated on Cardiomyocyte apoptosis and proliferation (p=<0.0001). Inhibition of TRPC6 and CaMKII with SAR7334 and KN-93 significantly alleviated high glucose-induced cardiomyocyte apoptosis and proliferation inhibition.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: